4//SEC Filing
ARCH Venture Fund VII, L.P. 4
Accession 0001012975-19-000489
CIK 0001556263other
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 7:26 PM ET
Size
17.8 KB
Accession
0001012975-19-000489
Insider Transaction Report
Form 4
Arch Venture Fund VII LP
10% Owner
Transactions
- Sale
Common Stock
2019-07-16$7.81/sh−25,779$201,277→ 4,276,572 total - Sale
Common Stock
2019-07-15$8.27/sh−2,700$22,316→ 4,302,051 total - Sale
Common Stock
2019-07-17$7.70/sh−34,521$265,687→ 4,242,051 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.40, inclusive. The reporting person undertakes to provide to Syros Pharmaceuticals, Inc., any security holder of' Syros Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.825, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.5775 to $7.755, inclusive.
- [F4]Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F5]The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001402439
Filing Metadata
- Form type
- 4
- Filed
- Jul 16, 8:00 PM ET
- Accepted
- Jul 17, 7:26 PM ET
- Size
- 17.8 KB